Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis

Ebru Yılmaz; Özge Pasin; Loiane Cristina de Souza; Guilherme Torres Vilarino; Alexandro Andrade; Camila Gusmão Vicente de Carvalho; Barbara Bayeh; Fernando Henrique Carlos de Souza; Renata Miossi; Pleiades Tiharu Inaoka; Takashi Matsushita; Naoki Mugii; Samuel Katsuyuki Shinjo

doi:10.4081/reumatismo.2024.1709

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

Search Results

##search.searchResults.foundPlural##

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

278-285

17-03-2014

https://doi.org/10.4081/reumatismo.2013.682

2631

PDF: 1361
Possible relationship between certolizumab pegol and arrhythmias: report of two cases

R. Talotta, F. Atzeni, A. Batticciotto, D. Ventura, P. Sarzi-Puttini

104-108

09-09-2016

https://doi.org/10.4081/reumatismo.2016.869

1556

PDF: 947
Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni

83-89

09-09-2016

https://doi.org/10.4081/reumatismo.2016.875

1842

PDF: 899

IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 518
Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

G. Carlino, M. Fornaro, L. Santo, R. Bucci, A. Semeraro, L. Quarta, F. D'Onofrio, A. Marsico, C. Zuccaro, P.C. Falappone, D. Mazzotta, F.P. Cantatore, M. Muratore, F. Iannone

24-30

01-04-2019

https://doi.org/10.4081/reumatismo.2019.1154

1551

PDF: 1063
Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

26-06-2025

https://doi.org/10.4081/reumatismo.2025.1792

52

PDF: 14
Are biological drugs safe in pregnancy?

A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

304-317

31-03-2015

https://doi.org/10.4081/reumatismo.2014.798

3723

PDF: 2400
Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti

24-06-2024

https://doi.org/10.4081/reumatismo.2024.1608

1464

PDF: 534
Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1602

1789

PDF: 430
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali

17-07-2023

https://doi.org/10.4081/reumatismo.2023.1544

1000

PDF: 543
A short history of anti-rheumatic therapy. II. Aspirin

G. Pasero, P. Marson

148-156

https://doi.org/10.4081/reumatismo.2010.148

2431

PDF: 1483
Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

08-05-2023

https://doi.org/10.4081/reumatismo.2023.1559

1582

PDF: 872
Safety of anti-TNFa biological drugs

F. Trotta, G. Valentini

34-39

https://doi.org/10.4081/reumatismo.2005.4s.34

1130

PDF: 1125
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio

27-01-2025

https://doi.org/10.4081/reumatismo.2025.1694

1524

PDF: 19
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

75-78

27-05-2013

https://doi.org/10.4081/reumatismo.2013.75

2959

PDF: 888
Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience

V. Gerloni, I. Pontikaki, M Gattinara, F. Fantini

244-261

https://doi.org/10.4081/reumatismo.2007.244

1288

PDF: 1104

1 - 15 of 15 items

Search

Search Results

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

Possible relationship between certolizumab pegol and arrhythmias: report of two cases

Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Are biological drugs safe in pregnancy?

Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

A short history of anti-rheumatic therapy. II. Aspirin

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

Safety of anti-TNFa biological drugs

Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience

authors

reviewers

Categories

indexing

Keywords